Catalio Capital Management
Portfolio in Switzerland · United States: 2 funded startups tracked by Uback, 2 of them in a ranking.
Portfolio on Uback2startups, 2 countries
In a ranking2ranked by AI-estimated valuation
On the Radar0eligible, not ranked
Latest deal trackedSep 2026Enveda
Portfolio on Uback
Sorted by Uback rank, then Radar by last round| Company | Uback | Sector | Round backed | Valuation (AI) |
|---|---|---|---|---|
| GlycoEra | #16 Switzerland | Biotech › autoimmune protein degraders | Series B · USD 130M · May 2025 | Hundreds of M$ |
| Enveda | #4 AI drug discovery | Healthtech › Biotech › AI drug discovery | Series E · USD 311M · Sep 2026 | Unicorn |
Only startups that meet Uback’s eligibility rules are shown. Amounts are round sizes, not the fund’s share. Rounds as reported by public sources.
By sector
Deals tracked per year
12025
12026
Co-investors
Novo Holdings · Bristol Myers Squibb · ICONIQ
Investors that joined the same rounds, as reported by public sources.
Last updated: Oct 2026Report a missing dealReport an error
Uback is a content publisher. It provides no investment advice, receives no mandate and takes part in no transaction.